title: Future pharmacologic targets for acute and preventive treatments of migraine.
abstract: Advances in investigative research (e.g., functional magnetic resonance imaging) have made it possible to study putative migraine processes and better understand the pathophysiology of the disorder. Consequently, the apparent opposing vascular and neuronal theories of migraine are now reconciled into a neurovascular hypothesis that pieces together migrainous events and allows us to better target such events in the hope of providing safe and effective therapies. Parallel discoveries in the fields of pharmacology, physiology, genetics and other biomedical disciplines will lead to the development of optimal migraine therapeutics. Such discoveries have already yielded some major enhancement in acute migraine treatment with the development of sumatriptan (Imitrex, GlaxoSmithKline) and other triptans and the trajectory is likely to be exponential. Novel targets, such as calcitonin gene-related peptide antagonists and inhibitors of excitatory glutamatergic receptors, are leading the pack but many other promising targets are in development. The post-sumatriptan decades will witness treatment strategies that will improve the therapeutic index of acute therapies and others which will effectively and safely prevent migraine attacks.
authors.affiliation: Rosalind Franklin University of Medicine and Science, 3333 Green Bay Road, North Chicago, IL 60064, USA. thomasbuchanan@finchcms.edu
authors.forename: Thomas M
authors.initials: TM
authors.lastname: Buchanan
authors.forename: Nabih M
authors.initials: NM
authors.lastname: Ramadan
authors.forename: Sheena
authors.initials: S
authors.lastname: Aurora
mesh_terms: D000208:Acute Disease; D000818:Animals; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends*; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy* / Q000517:prevention & control*; D018015:Receptors, Calcitonin Gene-Related Peptide / Q000502:physiology; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use; D014662:Vasoconstrictor Agents / Q000627:therapeutic use
chemical_list: D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D018015:Receptors, Calcitonin Gene-Related Peptide; D017366:Serotonin Receptor Agonists; D014662:Vasoconstrictor Agents